1. Minimal Residual Disease in CLL

3. Program Objectives

4. Definition of MRD Negativity

5. Outcomes in Clinical Trials

6. Very Deep MRD May Yield CLL “Cure”

7. MRD Negativity Predicts PFS After Treatment With FC and FCR

8. MRD Negativity Predicts PFS After Treatment With G-Clb and R-Clb

9. MRD Negativity Predicts PFS After Treatment With Alemtuzumab

10. MRD Negativity With Ibrutinib ± Rituximab

11. MRD Negativity With BR ± Ibrutinib

12. MRD Negativity With VenR

13. MRD Negativity With Venetoclax + Obinutuzumab

14. MRD Negativity With Venetoclax + Ibrutinib

15. Sequential Benefit in PFS With Log Reduction in MRD

16. Changes in Assessment of MRD Depth and Effectiveness of Treatment

17. Comparison of MRD Assessment Techniques

18. PB vs BM MRD With Chemoimmunotherapy

19. PB vs BM MRD With Ibrutinib + Obinutuzumab or Venetoclax

20. PB vs BM MRD With Novel Agents

21. PB vs BM MRD Assessment in Clinical Practice

22. Interpreting Historical MRD Assessment Data in the Era of NGS

23. MRD Negativity as an Endpoint in CLL Trials

24. Using MRD Status to Guide Treatment Decisions: Potential Implications

25. Using MRD Status to Guide Treatment Decisions: CIT and Novel Monotherapies

26. Using MRD Status to Guide Treatment Decisions: Novel Combinations

27. Anticipating Duration of MRD Negativity

28. Looking Ahead

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)